1. Home
  2. MXCT vs WHWK Comparison

MXCT vs WHWK Comparison

Compare MXCT & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

N/A

Current Price

$1.56

Market Cap

155.8M

Sector

Health Care

ML Signal

N/A

Logo Whitehawk Therapeutics Inc.

WHWK

Whitehawk Therapeutics Inc.

N/A

Current Price

$3.23

Market Cap

164.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MXCT
WHWK
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
164.8M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
MXCT
WHWK
Price
$1.56
$3.23
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$4.11
★ $7.71
AVG Volume (30 Days)
★ 1.4M
334.6K
Earning Date
11-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 86.02
EPS
★ N/A
N/A
Revenue
★ $33,026,000.00
$7,145,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.53
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.64
$1.97
52 Week High
$1.81
$5.50

Technical Indicators

Market Signals
Indicator
MXCT
WHWK
Relative Strength Index (RSI) 63.38 42.25
Support Level $1.17 $2.85
Resistance Level N/A $3.88
Average True Range (ATR) 0.12 0.21
MACD 0.04 0.05
Stochastic Oscillator 75.12 56.06

Price Performance

Historical Comparison
MXCT
WHWK

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About WHWK Whitehawk Therapeutics Inc.

Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.

Share on Social Networks: